GENSF Stock Chart & Stats
$30.92
$0.00(0.00%)
At close: 4:00 PM EDT
$30.92
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$25.41 - $41.20
Previous CloseN/A
Volume25.00
Average Volume (3M)20.00
Market Cap
$1.96B
Enterprise Value$1.51B
Total Cash (Recent Filing)$43.70M
Total Debt (Recent Filing)$107.50M
Price to Earnings (P/E)5.3
Beta0.28
Next Earnings
Feb 25, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.39%
Share Statistics
EPS (TTM)4.31
Shares Outstanding65,592,570
10 Day Avg. Volume20
30 Day Avg. Volume20
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.85
Price to Sales (P/S)2.16
P/FCF Ratio18.20
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue2.29
Enterprise Value/Gross Profit2.44
Enterprise Value/Ebitda11.74
Forecast
1Y Price Target
$40.89Price Target Upside32.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.01
Revenue Forecast (FY)$8.73M
Bulls Say, Bears Say
Bulls Say
Balance Sheet DeleveragingMaterial debt reduction and higher equity have strengthened Genus's financial resilience and lowered leverage risk. A healthier capital structure should preserve flexibility to fund research, support customers, pursue growth opportunities, and maintain shareholder returns through the next several quarters.
Operating Profit And Margin GrowthBroad-based operating profit and margin improvement indicates that Genus is converting revenue into earnings more efficiently across its businesses. Sustained productivity benefits, especially from ABS's improvement program, can support stronger earnings quality and investment capacity over time.
PRP Commercialization ProgressRegulatory progress for PRRS-resistant pig technology creates a potentially differentiated growth platform beyond Genus's established genetics portfolio. Additional approvals and early commercialization can build customer, supply, and data foundations for a new recurring revenue opportunity.
Bears Say
North American Disease PressureLivestock disease pressure is directly reducing customer production and royalty-linked revenue in North America. Management expects the headwind to continue into the first half of FY 2027, so recovery depends partly on normalization of operating conditions outside Genus's immediate control.
Weak Dairy Market ConditionsPersistent dairy-market weakness can constrain farmer spending and reduce demand for bovine genetics, limiting ABS volume growth even where Sexcel performs well. Continued depressed prices may therefore delay a broader recovery in the segment and make near-term growth more uneven.
Volatile Earnings QualityThe sharp profit increase despite lower revenue raises questions about how much of the improvement is repeatable operating performance. Earlier margin compression and inconsistent profitability make future earnings less predictable, requiring continued execution to demonstrate durable underlying progress.
Genus plc News
GENSF FAQ
What was Genus PLC’s price range in the past 12 months?
Genus PLC lowest stock price was $25.41 and its highest was $41.20 in the past 12 months.
What is Genus PLC’s market cap?
Genus PLC’s market cap is $1.96B.
When is Genus PLC’s upcoming earnings report date?
Genus PLC’s upcoming earnings report date is Feb 25, 2027 which is in 128 days.
How were Genus PLC’s earnings last quarter?
Genus PLC released its earnings results on Sep 10, 2026. The company reported $5.146 earnings per share for the quarter.
Is Genus PLC overvalued?
According to Wall Street analysts Genus PLC’s price is currently Undervalued.
Does Genus PLC pay dividends?
Genus PLC pays a Semiannually dividend of $0.319 which represents an annual dividend yield of 1.39%. See more information on Genus PLC dividends here
What is Genus PLC’s EPS estimate?
Genus PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genus PLC have?
Genus PLC has 65,592,570 shares outstanding.
What happened to Genus PLC’s price movement after its last earnings report?
Genus PLC reported an EPS of $5.146 in its last earnings report. Following the earnings report the stock price went down -2.947%.
Which hedge fund is a major shareholder of Genus PLC?
Currently, no hedge funds are holding shares in GENSF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Genus plc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$40.89 (32.23% Upside)
$40.89 (32.23% Upside)
Blogger Sentiment
Bullish
GENSF Sentiment 100%
Sector Average 66%
Sector Average 66%
Insider Transactions
Sold Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.00%
12-Months-Change
Fundamentals
Return on Equity
44.90%
Trailing 12-Months
Asset Growth
13.27%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Genus PLC
Genus plc is a global animal genetics company with operations spanning North America, Latin America, the UK, continental Europe, the Middle East, Russia, Africa, and Asia. The business is divided into three key segments: Genus PIC, Genus ABS, and Genus Research and Development. Under its PIC brand, the company provides breeding stock, including sows, boars, and semen, to develop pigs with specific characteristics optimized for pork production. Similarly, for cattle, its ABS, Genus, and Bovec brands offer bull semen and embryos designed to produce calves with advantageous traits for either milk or beef output. Farmers also benefit from a range of specialized technical services, such as semen sexing and reproductive solutions. Genus plc is also strategically collaborating with Beijing Capital Agribusiness Co. Ltd on the research, development, and regulatory approval of porcine reproductive and respiratory syndrome virus (PRRSV)-resistant pigs in China. The company was established in 1994 and is based in Basingstoke, United Kingdom.
GENSF Stock 12 Month Forecast
Average Price Target
$40.89
▲(32.23% Upside)
Technical Analysis
Bioventix
―
Oxford BioDynamics
―
Fusion Antibodies Plc
―
4basebio UK Societas
―
Oxford Nanopore Technologies PLC
―
Ownership Overview
0.28% Insiders
9.91% Mutual Funds
― Other Institutional Investors
81.50% Public Companies and
Individual Investors










